(2E)-2-(6,6-dimethyl-4-oxo-1-phenyl-1,4,6,7-tetrahydro-5H-indazol-5-ylidene)hydrazinecarbothioamide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: (2E)-2-(6,6-dimethyl-4-oxo-1-phenyl-1,4,6,7-tetrahydro-5H-indazol-5-ylidene)hydrazinecarbothioamide
• 英文别名: [(E)-(6,6-dimethyl-4-oxo-1-phenyl-7H-indazol-5-ylidene)amino]thiourea
• 化学式: C₁₆H₁₇N₅OS
• 分子量: 327.4
• InChiKey: CQTPVXGSCLNRRW-RGEXLXHISA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  23
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  117
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• Use of Inhibitors of Scavenger Receptor Class Proteins for the Treatment of Infectious Diseases
  申请人：Hannus Michael

  公开号：US20090324580A1

  公开（公告）日：2009-12-31

  The present invention relates to the use of inhibitors of scavenger receptor class proteins, in particular ScarB1 for the production of a medicament for treatment of and/or prophylaxis against infections, involving liver cells and/or hematopoietic cells, in particular malaria.
• USE OF INHIBITORS OF SCAVENGER RECEPTOR CLASS PROTEINS FOR THE TREATMENT OF INFECTIOUS DISEASES
  申请人：HANNUS MICHAEL

  公开号：US20120276121A1

  公开（公告）日：2012-11-01

  The present invention relates to the use of inhibitors of scavenger receptor class proteins, in particular ScarB1 for the production of a medicament for treatment of and/or prophylaxis against infections, involving liver cells and/or hematopoietic cells, in particular malaria.
• US8507546B2
  申请人：——

  公开号：US8507546B2

  公开（公告）日：2013-08-13
• [EN] USE OF INHIBITORS OF SCAVENGER RECEPTOR CLASS PROTEINS FOR THE TREATMENT OF INFECTIOUS DISEASES<br/>[FR] UTILISATION D'INHIBITEURS DE PROTÉINES DE LA CLASSE DES RÉCEPTEURS ÉBOUEURS DANS LE TRAITEMENT DE MALADIES INFECTIEUSES
  申请人：CENIX BIOSCIENCE GMBH

  公开号：WO2007101710A1

  公开（公告）日：2007-09-13

  (EN) The present invention relates to the use of inhibitors of scavenger receptor class proteins, in particular ScarB1 for the production of a medicament for treatment of and/or prophylaxis against infections, involving liver cells and/or hematopoietic cells, in particular malaria.(FR) La présente invention concerne l'utilisation d'inhibiteurs de protéines de la classe des récepteurs éboueurs, en particulier le ScarB1, dans la production d'un médicament destiné au traitement et/ou à la prophylaxie d'infections impliquant des cellules hépatiques et/ou hématopoïétiques, en particulier du paludisme.